Literature DB >> 29764340

In vitro and in vivo anti-cancer activity of silymarin on oral cancer.

Dong-Hoon Won1, Lee-Han Kim2, Boonsil Jang3, In-Hyoung Yang2, Hye-Jeong Kwon1, Bohwan Jin4, Seung Hyun Oh5, Ju-Hee Kang5, Seong-Doo Hong1, Ji-Ae Shin1, Sung-Dae Cho1.   

Abstract

Silymarin, a standardized extract from milk thistle fruits has been found to exhibit anti-cancer effects against various cancers. Here, we explored the anti-cancer activity of silymarin and its molecular target in human oral cancer in vitro and in vivo. Silymarin dose-dependently inhibited the proliferation of HSC-4 oral cancer cells and promoted caspase-dependent apoptosis. A human apoptosis protein array kit showed that death receptor 5 may be involved in silymarin-induced apoptosis, which was also shown through western blotting, immunocytochemistry, and reverse transcription-polymerase chain reaction. Silymarin increased cleaved caspase-8 and truncated Bid, leading to accumulation of cytochrome c. In addition, silymarin activated death receptor 5/caspase-8 to induce apoptotic cell death in two other oral cancer cell lines (YD15 and Ca9.22). Silymarin also suppressed tumor growth and volume without any hepatic or renal toxicity in vivo. Taken together, these results provide in vitro and in vivo evidence supporting the anti-cancer effect of silymarin and death receptor 5, and caspase-8 may be essential players in silymarin-mediated apoptosis in oral cancer.

Entities:  

Keywords:  Silymarin; apoptosis; caspase-8; death receptor 5; oral cancer

Mesh:

Substances:

Year:  2018        PMID: 29764340     DOI: 10.1177/1010428318776170

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  8 in total

Review 1.  Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions.

Authors:  Tomas Koltai; Larry Fliegel
Journal:  J Evid Based Integr Med       Date:  2022 Jan-Dec

Review 2.  How Should the Worldwide Knowledge of Traditional Cancer Healing Be Integrated with Herbs and Mushrooms into Modern Molecular Pharmacology?

Authors:  Yulia Kirdeeva; Olga Fedorova; Alexandra Daks; Nikolai Barlev; Oleg Shuvalov
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-14

3.  Silymarin inhibits the progression of Ehrlich solid tumor via targeting molecular pathways of cell death, proliferation, angiogenesis, and metastasis in female mice.

Authors:  Maggie E Amer; Maher A Amer; Azza I Othman; Doaa A Elsayed; Mohamed Amr El-Missiry; Omar A Ammar
Journal:  Mol Biol Rep       Date:  2022-03-19       Impact factor: 2.742

4.  Silymarin induces inhibition of growth and apoptosis through modulation of the MAPK signaling pathway in AGS human gastric cancer cells.

Authors:  Sung-Hyun Kim; Gang-Sik Choo; Eun-Seon Yoo; Joong-Seok Woo; So-Hee Han; Jae-Han Lee; Ji-Youn Jung
Journal:  Oncol Rep       Date:  2019-08-28       Impact factor: 3.906

5.  New therapeutic modalities in drug discovery and development: Insights & opportunities.

Authors:  Manfred Kansy; Giulia Caron
Journal:  ADMET DMPK       Date:  2021-12-15

Review 6.  Mechanistic Insights into the Pharmacological Significance of Silymarin.

Authors:  Karan Wadhwa; Rakesh Pahwa; Manish Kumar; Shobhit Kumar; Prabodh Chander Sharma; Govind Singh; Ravinder Verma; Vineet Mittal; Inderbir Singh; Deepak Kaushik; Philippe Jeandet
Journal:  Molecules       Date:  2022-08-21       Impact factor: 4.927

7.  The Influence of Lycopene, [6]-Gingerol, and Silymarin on the Apoptosis on U-118MG Glioblastoma Cells In Vitro Model.

Authors:  Justyna Czarnik-Kwaśniak; Konrad Kwaśniak; Paulina Kwasek; Elżbieta Świerzowska; Agata Strojewska; Jacek Tabarkiewicz
Journal:  Nutrients       Date:  2019-12-30       Impact factor: 5.717

8.  Pseudolaric Acid B Induces Growth Inhibition and Caspase-Dependent Apoptosis on Head and Neck Cancer Cell lines through Death Receptor 5.

Authors:  Su-Jung Choi; Chi-Hyun Ahn; In-Hyoung Yang; Bohwan Jin; Won Woo Lee; Ji-Hoon Kim; Min-Hye Ahn; Neeti Swarup; Kyoung-Ok Hong; Ji-Ae Shin; Nam-Tae Woo; Seong Doo Hong; Jae-Il Lee; Sung-Dae Cho
Journal:  Molecules       Date:  2019-10-16       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.